Cost-utility analysis of the inhaled steroids available in a developing country for the management of pediatric patients with persistent asthma

Journal of Asthma

Volumn 50, Issue 4, 2013, Pages 410-418

  Rodríguez Martínez, Carlos E ^a,b,c   Sossa Briceño, Mónica P ^d   Castro Rodriguez, Jose A ^e  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b UNIVERSIDAD EL BOSQUE   (Colombia)

^c HOSPITAL MILITAR CENTRAL   (Colombia)

^d Hospital Reina Sofia   (Colombia)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Asthma; Children; Cost effectiveness; Developing countries; Inhaled corticosteroids; Quality adjusted life years

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; CICLESONIDE; FLUTICASONE PROPIONATE;

ADULT; ASTHMA; COST UTILITY ANALYSIS; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PERSISTENT ASTHMA; QUALITY ADJUSTED LIFE YEAR; REVIEW; SYSTEMATIC REVIEW (TOPIC);

EID: 84876276667     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2013.767909     Document Type: Review

References (66)

1. Centers for Disease Control and Prevention (CDC). Vital signs: Asthma prevalence, disease characteristics, and self-management education-United States, 2001-2009. MMWR Morb Mortal Wkly Rep 2011; 60:547-552.
2. Dennis RJ, Caraballo L, García E, Rojas MX, Rondon MA, Pérez A, Aristizabal G, Peñaranda A, Barragan AM, Ahumada V, Jimenez S. Prevalence of asthma and other allergic conditions in Colombia 2009-2010: A cross-sectional study. BMC Pulm Med 2012; 13:12-17.
3. Garcia E, Aristizabal G, Vasquez C, Rodriguez-Martinez CE, Sarmiento OL, Satizabal CL. Prevalence and factors associated with current asthma symptoms in school children aged 6-7 and 13-14 years old in Bogota, Colombia. Pediatr Allergy Immunol 2008; 19:307-314.
4. GINA Report. Global Strategy for asthma management and prevention, global initiative for asthma. 2011. Available at: http://www.ginasthma.org. Accessed September 17, 2012.
5. Johansson G, Andreasson EB, Larsson PE, Vogelmeier CF. Cost effectiveness of budesonide/formoterol for maintenance and reliever therapy versus salmeterol/fluticasone plus salbutamol in the treatment of asthma. Pharmaeconomics 2006; 24:695-708.
6. Tina Shih YC, Mauskopf J, Borker R. A cost-effectiveness analysis of first-line controller therapies for persistent asthma. Pharmacoeconomics 2007; 25:577-590.
7. Price MJ, Briggs AH. Development of an economic model to assess the cost-effectiveness of asthma management strategies. Pharmaeconomics 2002; 20:183-194.
8. O'Connor RD, Nelson H, Borker R, Emmett A, Jhingran P, Rickard K, Dorinsky P. Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent asthma. Pharmacoeconomics 2004; 22:815-825.
9. Sheth K, Borker R, Emmett A, Rickard K, Dorinsky P. Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent asthma. Pharmaeconomics 2002; 20:909-918.
10. Johansson G, Price MJ, Sondhi S. Cost-effectiveness analysis of salme-terol/fluticasone propionate 50/100μg vs. fluticasone propionate 100μg in adults and adolescents with astma. III: Results. Pharmaeconomics 1999; 16(Suppl 2):15-21.
11. Stempel DA, Stanford RH, Thwaites R, Price MJ. Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma. Clin Ther 2000; 22:1562-1574.
12. Wang L, Hollenbeak CS, Mauger DT, Zeiger RS, Paul IM, Sorkness CA, Lemanske RF Jr, Martinez FD, Strunk RC, Szefler SJ, Taussig LM; Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute. Cost-effectiveness analysis of flutica-sone versus montelukast in children with mild-to-moderate persistent asthma in the pediatric asthma controller trial. J Allergy Clin Immunol 2011; 127:161-166.
13. Rand CS, Wise RA. Measuring adherence to asthma medication regimens. Am J Respir Crit Care Med 1994; 149:S69-S76.
14. Rubio-Terrés C, Echevarría A. Modelos de Markov: Una herramienta útil para el análisis farmacoeconómico. Pharmacoeconomics-Spanish Reasearch Articles 2006; 3:71-78.
15. Briggs A, Sculpher M. An introduction to Markov modeling for economic evaluation. Pharmacoeconomics 1998; 13:397-409.
16. Mallol J, Aguirre V. Once versus twice daily budesonide metered-dose inhaler in children with mild to moderate asthma: Effect on symptoms and bronchial responsiveness. Allergol et Immunopathol 2007; 35:25-31.
17. Johasson G, Carlsen KH, Mowinckel P. Asthma drug adherence in a long term clinical trial. Arch Dis Child 2000; 83:330-333.
18. Phillips K, Oborne J, Lewis S, Harrison TW, Tattersfield AE. Time course of action of two inhaled corticosteroids, fluticasone propionate and budesonide. Thorax 2004; 59:26-30.
19. Hoekx JC, Hedlin G, Pedersen W, Sorva R, Hollingworth K, Efthimiou J. Fluticasone propionate compared with budesonide: A double-blind trial in asthmatic children using powder devices at a dosage of 400 μg/day. Eur Respir J 1996; 9:2263-2272.
20. Verberne AA, Frost C, Roorda RJ, van der Laag H, Kerrebijn KF. One year treatment with salmeterol compared with beclomethasone in children with asthma. Am J Respir Crit Care Med 1997; 156:688-695.
21. Connett GJ, Warde C, Wooler E, Lenney W. Use of budesonide in severe asthmatics aged 1-3 years. Arch Dis Child 1993; 69:351-355.
22. Nielsen KG, Bisgaard H. The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2 to 5 year-old asthmatic children. Am J Respir Crit Care Med 2000; 162:1500-1506.
23. Lönnkvist K, Hellman C, Lundahl J, Halldén G, Hedlin G. Eosinophil markers in blood, serum, and urine for monitoring the clinical course in childhood asthma: Impact of budesonide treatment and withdrawal. J Allergy Clin Immunol 2001; 107:812-817.
24. Gelfand EW, Georgitis JW, Noonan M, Ruff ME. Once-daily ciclesonide in children: Efficacy and safety in asthma. J Pediatr 2006; 148:377-381.
25. Katz Y, Lebas FX, Medley HV, Robson R. Fluticasone propionate 50mcg BID versus 100mcg BID in the treatment of children with persistent asthma. Clin Ther 1998; 20:424-437.
26. Gleeson JGA, Price JF. Controlled trial of budesonide given by the Nebuhaler in preschool children with asthma. BMJ 1988; 297:163-166.
27. Boner AL, Piacentini GL, Bonizzato C, Dattoli V, Sette L. Effect of inhaled beclomethasone dipropionate on bronchial hyperreactivity in asthmatic children during maximal allergen exposure. Pediatr Pulmonol 1991; 10:2-5.
28. Benito-Fernández J, Onis-González E, Alvarez-Pitti J, Capapé-Zache S, Vázquez-Ronco MA, Mintegi-Raso S. Factors associated with short-term clinical outcomes after acute treatment of asthma in a pediatric emergency department. Pediatr Pulmonol 2004; 38:123-128.
29. Kattan M, Mitchell H, Eggleston P, Gergen P, Crain E, Redline S, Weiss K, Evans R 3rd, Kaslow R, Kercsmar C, Leickly F, Malveaux F, Wedner HJ. Characteristics of inner-city children with asthma: The national cooperative inner-citystudy. Pediatr Pulmonol 1997; 24:253-262.
30. Adams NP, Bestall JB, Malouf R, Lasserson TJ, Jones PW. Beclomethasone versus placebo for chronic asthma. Cochrane Database Syst Rev 2005; (1), Art. No. CD002738. DOI: 10.1002/14651858. CD002738.pub2.
31. Adams N, Bestall J, Jones PW. Budesonide versus placebo for chronic asthma in children and adults. Cochrane Database Syst Rev 1999; (4), Art No. CD003274 DOI: 10.1002/14651858.CD003274.
32. Adams NP, Bestall JC, Lasserson TJ, Jones PW. Cates CJ. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2005 (4), Art. No. CD003135. DOI: 10.1002/14651858.CD003135.pub3.
33. Manning P, Gibson PG, Lasserson TJ. Ciclesonide versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2008 (2), Art. No. CD006217. DOI: 10.1002/14651858. CD006217. pub2.
34. Pedersen S, Garcia Garcia ML, Manjra AL, Theron I, Engelstatter R. A comparative study of inhaled ciclesonide 160mcg/day and fluticasone propionate 176 mcg/day in children with asthma. Pediatr Pulmonol 2006; 41:954-961.
35. Gustafsson P, Tsanakas J, Gold M, Primhak R, Radford M, Gillies E. Comparison of the efficacy and safety of inhaled fluticasone propionate 200mcg/day with inhaled beclomethasone dipropionate 400mcg/day in mild and moderate asthma. Arch Dis Child 1993; 69:206-211.
36. Pedersen S, Warner J, Wahn U, Staab D, Le Bourgeois M, Van Essen-Zandvliet E, Arora S, Szefler SJ; Pediatric Study Group. Growth, systemic safety, and efficacy during 1 year of asthma treatment with different beclomethasone dipropionate formulations: An open-label, randomized comparison of extrafine and conventional aerosols in children. Pediatrics 2002; 109:e92.
37. Springer C, Avital A, Maayan CH, Rosler A, Godfrey S. Comparison of budesonide and beclomethasone dipropionate for treatment of asthma. Arch Dis Child 1987; 62: 815-819.
38. Szefler SJ, Warner J, Staab D, Wahn U, Le Bourgeois M, van Essen-Zandvliet EE, Arora S, Pedersen S; Pediatric Study Group. Switching from conventional to extrafine aerosol beclomethasone dipropionate therapy in children: A 6-month, open-label randomized trial. J Allergy Clin Immunol 2002; 110:45-50.
39. Yiallourous PK, Milner AD, Conway E, Honour JH. Adrenal function and high dose inhaled corticosteroids for asthma. Arch Dis Child 1997; 76:405-410.
40. Francis RS. Long-term beclomethasone dipropionate aerosol therapy in juvenile asthma. Thorax 1976; 31:309-314.
41. Varsano I, Volovitz B, Malik H, Amir Y. Safety of 1 year of treatment with budesonide in young children with asthma. J Allergy Clin Immunol 1990; 85:914-920.
42. Vermeulen JH, Gyurkovits K, Rauer H, Engelstatter R. Randomized comparison and safety of ciclesonide and budesonide in adolescents with severe asthma. Respir Med 2007; 101:2182-2191.
43. von Berg A, Engelstätter R, Minic P, Sréckovic M, Garcia Garcia ML, Latos T, Vermeulen JH, Leichtl S, Hellbardt S, Bethke TD. Comparison of the efficacy and safety of ciclesonide 160mcg once daily vs. budeso-nide 400mcg once daily in children with asthma. Pediatr Allergy Immunol 2007; 18:391-400.
44. Garcia Garcia ML, Wahn U, Gilles L, Swern A, Tozzi CA, Polos P. Montelukast, compared with fluticasone, for control of asthma among 6 to 14-year-old patients with mild asthma: The MOSAIC study. Pediatrics 2005; 116:360-369.
45. Briggs A, Claxton K, Sculpher M. Decision modeling for health economic evaluation. New York: Oxford University Press, 2006.
46. Chiou CF, Weaver MR, Bell MA, Lee TA, Krieger JW. Development of the multi-atribute pediatric asthma health outcome measure (PAHOM). Int J Qual Health Care 2005; 17:23-30.
47. Catálogo Farmacéutico Nacional. Available at: http://www.medicentro. com.co/CATALOGO-FARMA.htm. Accessed September 17, 2012.
48. British Guideline on the Management of Asthma. A national clinical guideline. British Thoracic Society. Scottish Intercollegiate Guidelines Network. Available at: http://www.sign.ac.uk/pdf/sign101.pdf. Accessed September 17, 2012.
49. Banco de la República, Colombia. Series estadísticas. Tasa de cambio. Santa Fe de Bogotá: Banco de la República; 2009. Available at: http://www.banrep.gov.co/series-estadisticas/see-ts-cam.htm. Accessed September 17, 2012.
50. O'Brien BJ, Drummond MF, Labelle RJ, Willan A. In search of power and significance: Issues in the design and analysis of stochastic cost-effectiveness studies in health care. Med Care 1994; 32:150-163.
51. Briggs AH, Goeree R, Blackhouse G, O'Brien B. Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 2002; 22:290-308.
52. Commission on Macroeconomics and Health World Health Organization (WHO). Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organization 2001.
53. Acceso a medicamentos esenciales: compras corporativas nacionales y implicancias para el nivel regional y local. Available at: http://www. eurosocialsalud.eu/files/docs/00064.pdf. Accessed September 17, 2012.
54. Adams N, Lasserson TJ, Cates CJ, Jones PW. Fluticasone versus beclo-methasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 2007 (4), Art. No. CD002310. DOI: 10.1002/14651858.CD002310.pub4.
55. Manning P, Gibson PG, Lasserson TJ. Ciclesonide versus other inhaled steroids for chronic asthma inchildren and adults. Cochrane Database Syst Rev 2008 (2), Art. No. CD007031. DOI: 10.1002/14651858.CD007031.
56. Sabin T, Gurumurthy P, Shilpa P, Jayaraj BS, Basavana Gowda H, Mahesh PA. Quality of life assessment in asthmatic patients receiving fluticasone compared with equipotent doses of beclomethasone or bude-sonide. Lung India 2005; 22:86-91.
57. Kelly HW. Establishing a therapeutic index for the inhaled corticoster-oids: Part I. Pharmacokinetic/pharmacodynamic comparison of the inhaled corticosteroids. J Allergy Clin Immunol 1998; 102:36-51.
58. Phillips GH. Structure-activity relationships of topically active steroids: The selection of fluticasone propionate. Respir Med 1990; 84(Suppl A):19-23.
59. Shaw RJ. Inhaled corticosteroids for adult asthma: Impact of formulation and delivery device on relative pharmacokinetics, efficacy and safety. Respir Med 1999; 93:149-160.
60. Anselmo M. Pediatric asthma controller therapy. Paediatr Drugs 2011; 13:11-17.
61. Allen DB. Safetyof inhaled corticosteroids in children. Pediatr Pulmonol 2002; 33:208-220.
62. Kelly HW, Sternberg AL, Lescher R, Fuhlbrigge AL, Williams P, Zeiger RS, Raissy HH, Van Natta ML, Tonascia J, Strunk RC; CAMP Research Group. Effects of inhaled glucocorticoids in childhood on adult height. N Engl J Med 2012; 367:904-912.
63. Barnes NC, Thwaites RMA, Price MJ. The cost-effectiveness of inhaled fluticasone propionate and budesonide in the treatment of asthma in adults and children. Respir Med 1999; 93:402-407.
64. Trakas K, Oh PI, Einarson TR, Shear NH. A health economic analysis of fluticasone propionate, budesonide, and beclomethasone dipropionate for the treatment of moderate to severe asthma. Value Health 1998; 1:62.
65. Neumann PJ. What next for QALYs? J Am Med Assoc 2011; 305:1806-1807.
66. UK Secretary of State for Health Department of Health. A new value-based approach to the pricing of branded medicines-a consultation. Available at: http://www.dh.gov.uk/en/Consultations/Liveconsultations/DH-122760. Accessed September 17, 2012.